Dogwood Therapeutics, Inc. (DWTX): Total Liabilities
$15.27M
As of 2025-12-31
$12.13M
As of 2026-06-30
+144.6%
3-year compound annual growth
+58.4%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.27M | -49.1% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $30.03M | n/m | 2026-03-18, Balance as of period end |
| 2023-12-31 | $358.5K | -65.6% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $1.04M | -18.2% | 2024-03-08, Balance as of period end |
| 2021-12-31 | $1.28M | -16.7% | 2023-03-14, Balance as of period end |
| 2020-12-31 | $1.53M | n/a | 2022-03-18, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | 2025-12-31 | $15.27M | -49.1% |
| vTv Therapeutics Inc. (VTVT) | 2025-12-31 | $25.46M | +6.2% |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $8.64M | -24.4% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $38.11M | +4.6% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $65.96M | +27.6% |
| Relmada Therapeutics, Inc. (RLMD) | 2025-12-31 | $7.49M | -27.2% |
| Eupraxia Pharmaceuticals Inc. (EPRX) | 2025-12-31 | $5.70M | +83.8% |
| Journey Medical Corp (DERM) | 2025-12-31 | $62.74M | +4.3% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $18.04M | -47.5% |
Compare DWTX, VTVT, STTK, PYXS side by side · Screen every company in Pharmaceutical Preparations ↗